This protocol addresses erythroderma occurring as a consequence of a drug reaction. Drug-related reactions are among the most recognised causes of erythroderma, and identifying the trigger is central to the clinical approach.
In case series, drug-related reactions represent the second most frequent cause of erythroderma, ranging from 11.3 to 21.6% of cases. Early recognition of the drug-reaction aetiology directly shapes management priorities.
The primary intervention in this setting is directed at the causative agent. The complete structured protocol — including the full sequence of steps, decision points, and supporting evidence — is available via the link below.
Resolution of erythroderma is the primary clinical target, commonly occurring within 2–6 weeks.
DOI: 10.1016/j.adengl.2018.05.033
In case series, drug-related reactions represent the second most frequent cause of erythroderma, ranging from 11.3 to 21.6% of cases.
Commonly resolves 2–6 weeks after discontinuation of offending drug.
View source ↗